

Attorney Docket No.: **28069-546**
(Formerly: 401930/SkyePharma)

ZM
AF\$

Applicants : Indu PARIKH, *et al.* Confirmation No.: 7862
U.S. Serial No. : 09/443,863 Customer No.: 35437
Filed : November 19, 1999
TC/A.U. : 1615
Examiner : Gollamudi S. Kishore
For : **Dispersible Phospholipid Stabilized Microparticles**

Mail Stop AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EXPRESS MAIL TRANSMITTAL


Date of Deposit: **January 31, 2006**

I hereby certify that the document(s) and fee(s) listed below are being deposited with the United States Patent and Trademark Office as Express Mail bearing Express Mail Label No. **EV781048138US** under 37 C.F.R. §1.10 in an envelope with prepaid postage on the date indicated above and addressed to **Mail Stop AF**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450:

1. Supplemental Information Disclosure Statement [2 pages], in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited References A111-A114;
4. Check No. 3015 in the amount of \$180.00;
5. Express Mail Transmittal (1 page), in duplicate; and
6. Return Receipt Postcard.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (212) 935-3000, New York, New York. The Director is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. **50-0311**, Reference No. **28069-546**, Customer No. **35437**.

Dated: January 31, 2006


Leslie A. Serunian, Reg. No. 35,353
MINTZ LEVIN COHN FERRIS
GLOVSKY and POPEO, P.C.
The Chrysler Center
666 Third Avenue, 24th Floor
New York, New York 10017
Telephone: (212) 935-3000
Facsimile: (212) 983-3115

Express Mail Label No.: EV781048138US
Date of Deposit: January 31, 2006



Attorney Docket No.: 28069-546
(Formerly: 401930/SkyePharma)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Indu PARIKH <i>et al.</i>		
SERIAL NUMBER:	09/443,863	EXAMINER:	Gollamudi S. Kishore
FILING DATE:	November 19, 1999	ART UNIT:	1615
CUSTOMER NO.:	35437	CONFIRMATION No.	7862
FOR:	DISPERSIBLE PHOSPHOLIPID STABILIZED MICROPARTICLES		

Mail Stop AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of a Final Office Action on the merits, and, accordingly, a fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. The Examiner is also respectfully requested to sign and date the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, Applicants make no representation: (1) that a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Applicants : Indu Parikh *et al.*
U.S. Serial No.: 09/443,863
Filing Date: November 19, 1999
Express Mail Label No.: EV781048138US

Attorney Docket No.: 28069-546
(Formerly: 401930/SkyePharma)

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **28069-546**, Customer No. **35437**.

Respectfully submitted,

MINTZ LEVIN COHN FERRIS GLOVSKY
& POPEO, P.C.

Date: January 31, 2006



Leslie A. Serunian, Reg. No. 35,353
MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO, P.C.
The Chrysler Center
666 Third Avenue, 24th Floor
New York, New York 10017
Tel: (212) 935-3000
Fax: (212) 983-3115
Direct Tel: (212) 692-6742

Express Mail Label No.: EV781048138US
Date of Deposit: January 31, 2006



Attorney Docket No.: 28069-546
(Formerly: 401930/SkyePharma)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Indu PARIKH <i>et al.</i>		
SERIAL NUMBER:	09/443,863	EXAMINER:	Gollamudi S. Kishore
FILING DATE:	November 19, 1999	ART UNIT:	1615
CUSTOMER NO.:	35437	CONFIRMATION No.	7862
FOR:	DISPERSIBLE PHOSPHOLIPID STABILIZED MICROPARTICLES		

Mail Stop AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of a Final Office Action on the merits, and, accordingly, a fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. The Examiner is also respectfully requested to sign and date the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, Applicants make no representation: (1) that a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Applicants : Indu Parikh *et al.*
U.S. Serial No.: 09/443,863
Filing Date: November 19, 1999
Express Mail Label No.: EV781048138US

Attorney Docket No.: 28069-546
(Formerly: 401930/SkyePharma)


The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **28069-546**, Customer No. **35437**.

Respectfully submitted,

MINTZ LEVIN COHN FERRIS GLOVSKY
& POPEO, P.C.

Date: January 31, 2006



Leslie A. Serunian, Reg. No. 35,353
MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO, P.C.
The Chrysler Center
666 Third Avenue, 24th Floor
New York, New York 10017
Tel: (212) 935-3000
Fax: (212) 983-3115
Direct Tel: (212) 692-6742

Express Mail Label No.: **EV781048138US**Date of Deposit: **January 31, 2006**

1 of 1

/ Please type a plus sign (+) in this box PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/443,863
	Filing Date	November 19, 1999
	First Named Inventor	Indu PARIKH
	Group Art Unit	1615
	Examiner Name	Gollamudi S. Kishore
	Attorney Docket Number	28069-546

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	A111	D. FERCEJ TEMELJOTOV, et al., "Solubilization and Dissolution Enhancement for Sparingly Soluble Fenofibrate", Acta Pharm. 46 (1996) pp. 131-136
	A112	J. SHEPHERD, "The Fibrates in Clinical Practice: Focus on Micronised Fenofibrate", Atherosclerosis 110 (Suppl.) (1994), S55-S63
	A113	J.P. GUICHARD et al., "A Comparison of the Bioavailability of Standard or Micronized Formulations of Fenofibrate", Current Therapeutic Research, Vol. 54, No. 5, November 1993, pp.610-614
	A114	M-T. SHEU, et al., "Dissolution Studies of Fenofibrate in the Ethanolic Medium", The Chinese Pharmaceutical Journal, Vol. 45, No. 1(1993), pp.43-51

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.